Achondroplasia Clinical Trial
Official title:
Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Achondroplasia: PROPEL OLE
This is a Phase 2, multicenter, open-label, extension (OLE) study to evaluate the long-term safety, tolerability, and efficacy of infigratinib, an FGFR 1-3-selective tyrosine kinase inhibitor, in subjects with ACH who previously completed a QED-sponsored interventional study, and potentially in additional subjects who are naïve to infigratinib treatment. Quality of Life assessments for this subject population will also be evaluated. Treatment-naïve subjects must have at least a 6-month period of growth assessment in the PROPEL study (Protocol QBGJ398 001) and will be enrolled in this OLE study only after a dose to be explored further is identified in Phase 2 Study QBGJ398-201.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05353192 -
A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Achondroplasia
|
Phase 4 | |
| Recruiting |
NCT05328050 -
Registry for Patients With Achondroplasia / Hypochondroplasia (OMPR-Ach/Hy)
|
||
| Completed |
NCT05659719 -
A Study to Learn About Recifercept in Patients With Achondroplasia
|
||
| Active, not recruiting |
NCT04554940 -
A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia
|
Phase 2 | |
| Completed |
NCT01435629 -
A Survey Collecting Data on Adult Height in Patients With Achondroplasia Treated With Somatropin
|
N/A | |
| Enrolling by invitation |
NCT06164951 -
A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia
|
Phase 3 | |
| Completed |
NCT03583697 -
A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia
|
Phase 2 | |
| Completed |
NCT01516229 -
Special Survey for Long Term Application
|
N/A | |
| Completed |
NCT03872531 -
Lifetime Impact Study for Achondroplasia
|
||
| Active, not recruiting |
NCT05598320 -
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia
|
Phase 2/Phase 3 | |
| Terminated |
NCT05813314 -
Bioequivalence Study to Compare Two Injection Devices for BMN 111 in Healthy Participants
|
Phase 1 | |
| Recruiting |
NCT04265651 -
Study of Infigratinib in Children With Achondroplasia
|
Phase 2 | |
| Recruiting |
NCT05603936 -
Adaption and Testing of the Quality of Life in Short Stature Youth (QoLISSY) Questionnaire for Parents With Children From 0-4
|
||
| Completed |
NCT03780153 -
The Norwegian Adult Achondroplasia Study
|
||
| Active, not recruiting |
NCT04085523 -
A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia
|
Phase 2 | |
| Enrolling by invitation |
NCT05929807 -
A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia
|
Phase 2/Phase 3 | |
| Completed |
NCT03875534 -
A Multi-center, Longitudinal, Observational Study of Children With Achondroplasia
|
||
| Terminated |
NCT03794609 -
Observational Study Investigating Clinical & Anthropometric Characteristics of Children With Achondroplasia.
|
||
| Active, not recruiting |
NCT03989947 -
An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia
|
Phase 2 | |
| Active, not recruiting |
NCT05246033 -
A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Multiple Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children With Achondroplasia
|
Phase 2 |